Journals / Anadolu Kardiyoloji Dergisi / 2003 / Cilt: 3 - Sayı: 4

İzole sıçan kalplerinde uzamış iskemi sonrasında Trimetazidine reperfüzyon sırasında gelişen düzelmeyi ilerletmektedir

Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia

Pages
303–308
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, both pre-treatment and treatment protocols with TMZ reduce the myocardial damage caused by global ischemia following reperfusion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Trimetazidine (TMZ) is a cellular anti-ischemic agent, which has been studied in clinical and experimental investigations, and was shown to have protective affects against myocardial ischemia and reperfusion injury.
📊
Key Findings & Data:In Group 2 (n=10) TMZ was given by intra-gastric gavage (3 mg/kg BW twice daily for 5 days) prior to operation and was added to the Krebbs-Henseleit perfusate to create a 10-6 M solution to perfuse the isolated rat hearts.
💡
Conclusion & Impact:Conclusion: In conclusion, both pre-treatment and treatment protocols with TMZ reduce the myocardial damage caused by global ischemia following reperfusion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Trimetazidine (TMZ) is a cellular anti-ischemic agent, which has been studied in clinical and experimental investigations, and was shown to have protective affects against myocardial ischemia and reperfusion injury. The major objective of this study was to investigate the cardio-protective effects of trimetazidine in prolonged global ischemia subjected Langendorff perfused rat hearts. Methods: Twenty rats (Male Sprague-Dawley) were divided into two study groups. In Group 2 (n=10) TMZ was given by intra-gastric gavage (3 mg/kg BW twice daily for 5 days) prior to operation and was added to the Krebbs-Henseleit perfusate to create a 10-6 M solution to perfuse the isolated rat hearts. Group 1 (n=10) reserved as control group and received saline at the same time period. All hearts were paced at 300 beats/min. After a 20-minute of stabilization period, hearts in both groups were arrested for 120 minutes with crystalloid cardioplegia. After ischemic period, the hearts were then reperfused for 30 minutes. Hemodynamic measurements from left ventricular latex balloon, coronary flow, and creatine kinase (CK-MB) and troponin T (cTnT) levels determined from the coronary effluent were analyzed at the end of stabilization and at every 10-min intervals during reperfusion, and results were compared between two groups. Results: No significant differences were observed in all entered hemodynamic and biochemical parameters between two groups at the end of the stabilization. However, peak systolic pressure, end diastolic pressure and +dP/dt values reflected improved mechanical myocardial recovery in Group 2 hearts after prolonged ischemia. Besides coronary flow measurements were higher in Group 2 compared with Group 1. CK-MB and cTnT levels indicated to less enzymatic damage in trimetazidine treated hearts during reperfusion. Conclusion: In conclusion, both pre-treatment and treatment protocols with TMZ reduce the myocardial damage caused by global ischemia following reperfusion. We could speculate that this beneficial effect of trimetazidine might be useful in open-heart surgery patients, who were subjected to global myocardial ischemia.

Özet

Amaç: Bu çalışma bir hücresel anti-iskemik ajan olan trimetazidine'nin (TMZ) izole sıçan kalpleri üzerine olan etkisini incelemek amacı ile gerçekleştirilmiştir. Yöntem: Çalışma amacı ile yirmi sıçan (erkek, Spraque-Dawley) iki gruba ayrılmıştır. Grup 2 (n=10) sıçanlara çalışma öncesi 5 gün boyunca 3 mg/kg TMZ oral yolla verilmiş, ardından çalışma esnasında Krebb's Henseleit perfüzyon sıvısına 10-6 M olacak şekilde eklenerek izole kalplere uygulanmıştır. Grup 1 (n=10) sıçanlar ise kontrol grubu olarak çalışılmış ve aynı protokole bağlı kalınarak bu grup sıçanlara TMZ yerine saline uygulanmıştır. Tüm kalpler çalışma esnasında 300 atım/dakika hızında pace edilmiştir. Yirmi dakika stabilizasyon periyodu sonunda her iki grupta da kalpler kristalloid kardiyopleji kullanılarak durduruldu ve 120 dakika global iskemi oluşturuldu. İskemi periyodu sonunda tüm kalpler Krebb's Henseleit solüsyonu ile 30 dakika reperfüze edildi. Deney başlangıcında sol ventriküle yerleştirilen lateks balon yardımı ile elde edilen hemodinamik veriler, koroner akım miktarı ve koroner akım örneklerinden çalışılan creatine kinaz (CK-MB) ve troponin T (cTnT) seviyeleri grupları karşılaştırmak amacı ile analiz edildi. Bulgular: İskemi öncesi elde edilen biyokimyasal ve hemodinamik parametreler incelendiğinde gruplar arasında anlamlı fark saptanamamıştır. Bununla birlikte iskemi sonrası ölçülen tüm parametreler reperfüzyon döneminde grup 2 kalplerde anlamlı olarak daha fazla miyokardiyal iyileşmeyi göstermiştir. Sonuç: Sonuç olarak, TMZ'nin ön tedavi ve hemen iskemi öncesi verilmesi ile oluşturulan tedavi kombinasyonu uzun süreli global iskemi sonrası reperfüzyon döneminde izole sıçan kalpleri üzerinde anlamlı derecede koruyucu etki göstermiştir.

🔖

Cite This Article

SEVİN, B., DERNEK, S., KURAL, T., İKİZLER, M. (2022). İzole sıçan kalplerinde uzamış iskemi sonrasında Trimetazidine reperfüzyon sırasında gelişen düzelmeyi ilerletmektedir. Anadolu Kardiyoloji Dergisi, Cilt: 3 - Sayı: 4, 303–308. https://ajindex.com/articles/437487

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Harpey C, Clauser P, Labrid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1988; 6: 292-312
  2. Bricaud H, Brottier L, Barat J, Combe C, Boussens B, Bonnet J. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy. Cardiovasc Drug Ther 1990; 4: 861-6
  3. Sellier P. Effects of trimetazidine on ergometric parameters in effort angina. Arch Mal Coeur 1986; 79: 1331-6
  4. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: Beneficial effect of the anti-ischemic agent trimetazidine. J Cardiovasc Pharmacol 1993; 21: 128-35
  5. D’hahan N, Taouil K, Dassouli A, Morel JE. Long-term therapy with trimetazidine in cardiomyopathic Syrian-hamster BIO16: 6. Eur J Pharmacol 1997; 328:163-74
  6. Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocrotaline-treated rats. Biochem Pharmacol 1988; 37: 4685-8
  7. Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of Trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110
  8. Kanazawa T. Effects of coronary vasodilators on the development of coronary collaterals in the coronary artery system. Nihon Rinsko 1974; 32: 57-65
  9. Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol.1995; 76 (Suppl): 45B-9B
  10. Veitch K, Maisin L, Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol 1995; 76 (Suppl): 25B-30B
  11. Vedrinne JM, Vedrinne C, Bompard D, Lehod JJ, Boissel JP, Champsaur G. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 1996; 82: 712-8
  12. Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992; 33: 486-91
  13. Noble MI, Belcher PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol 1995; 76 (Suppl): 41B-4
  14. Didier JP, Roux J, Violot D, Justrabo E. Effects of Trimetazidine on the rat isolated perfused heart in hypoxia: hemodynamic and histological study. Gaz Med 1984; 91 (Suppl 26.): 28-34